Compare · AKBA vs TCDA
AKBA vs TCDA
Side-by-side comparison of Akebia Therapeutics Inc. (AKBA) and Tricida Inc. (TCDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKBA and TCDA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- TCDA is the larger of the two at $550.1M, about 1.5x AKBA ($375.6M).
- AKBA has hit the wire 11 times in the past 4 weeks while TCDA has been quiet.
- AKBA has more recent analyst coverage (11 ratings vs 2 for TCDA).
- Company
- Akebia Therapeutics Inc.
- Tricida Inc.
- Price
- $1.41+1.08%
- $0.10-19.25%
- Market cap
- $375.6M
- $550.1M
- 1M return
- +56.76%
- -
- 1Y return
- -63.74%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2018
- News (4w)
- 11
- 0
- Recent ratings
- 11
- 2
Akebia Therapeutics Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Tricida Inc.
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest AKBA
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SVP, CFO, CBO & Treasurer Ostrowski Erik sold $62,181 worth of shares (56,019 units at $1.11), decreasing direct ownership by 8% to 616,616 units (SEC Form 4) to satisfy withholding tax
- Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
- Director Wolf Myles was granted 35,700 shares, increasing direct ownership by 27% to 169,081 units (SEC Form 4)
- Director Smith Cynthia was granted 35,700 shares, increasing direct ownership by 22% to 196,633 units (SEC Form 4)
- Director Rogers Michael W was granted 35,700 shares, increasing direct ownership by 22% to 197,429 units (SEC Form 4)
- Director Frieson Ron was granted 35,700 shares, increasing direct ownership by 28% to 165,200 units (SEC Form 4)
- Akebia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 33% to 145,100 units (SEC Form 4)
Latest TCDA
- SEC Form EFFECT filed by Tricida Inc.
- SEC Form 15-12G filed by Tricida Inc.
- SEC Form S-8 POS filed by Tricida Inc.
- SEC Form POSASR filed by Tricida Inc.
- SEC Form POS AM filed by Tricida Inc.
- Tricida Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits